Assess whether a CMC change is a comparability or a new product (cf8ff6)

Situation

Pharmacovigilance medical reviewer owns a CMC change is inside a mid-size sponsor after a complete response letter with advisory-committee question list that exposes a weak secondary endpoint as the only packet. An inspector asking for batch records you cannot produce this week is what changed the clock for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Pharmacovigilance medical reviewer in a mid-size sponsor after a complete response letter must choose A CMC change is a comparability / A new product using advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• An inspector asking for batch records you cannot produce this week is noise around an already-controlled CMC and Development Pathways process in a mid-size sponsor after a complete response letter, given advisory-committee question list that exposes a weak secondary endpoint.
• An inspector asking for batch records you cannot produce this week is the event in advisory-committee question list that exposes a weak secondary endpoint that forces A CMC change is a comparability for pharmacovigilance medical reviewer under Pharma & Life Sciences.
• Advisory-committee question list that exposes a weak secondary endpoint shows a one-file miss after an inspector asking for batch records you cannot produce this week, not a CMC and Development Pathways program failure.
• Advisory-committee question list that exposes a weak secondary endpoint cannot decide a CMC change is yet after an inspector asking for batch records you cannot produce this week; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Check whether advisory-committee question list that exposes a weak secondary endpoint supports the labeled claim pharmacovigilance medical reviewer would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in advisory-committee question list that exposes a weak secondary endpoint after an inspector asking for batch records you cannot produce this week.
• For this Pharma & Life Sciences CMC and Development Pathways file, read advisory-committee question list that exposes a weak secondary endpoint against an inspector asking for batch records you cannot produce this week and write the one fact that would move a CMC change is for pharmacovigilance medical reviewer.